YesWeHack Raises 26 Million Euros to Accelerate Its Growth and International Expansion
11.6.2024 09:00:00 EEST | Business Wire | Press release
YesWeHack, the global Bug Bounty and vulnerability management platform, announces a €26 million Series C funding round.
In a world where cyber risks are more strategic and complex than ever, YesWeHack will use this funding to invest in Artificial Intelligence, launch new innovative solutions and expand its international growth.
The round is led by Wendel, alongside new investors such as Adelie and Seventure Partners, as well as reinvestment from Bpifrance, Open CNP* and Eiffel Investment Group. YesWeHack is also delighted to welcome Renaud Deraison, Co-Founder of Tenable and Senior Advisor to Wendel Growth, to its Board of Directors.
YesWeHack is the leading security testing solution for organisations of all sizes. Its Bug Bounty platform mobilises a community of tens of thousands ethical hackers to test the security of its customers in an agile and cost-effective way, thus reducing their attack surface.
With more than 500 customers across 40 countries, YesWeHack covers all business sectors, including:
- 70% of “CAC 40” ** companies
- Global organisations such as Louis Vuitton, Decathlon and Tencent
- Telecoms companies such as Orange, Ooredoo and Telenor
- Unicorns such as Contentsquare, Doctolib and Blablacar
- Public institutions in countries such as France, Spain, Canada and Singapore
Since its last funding round in 2021, YesWeHack has increased by six times its annual recurring revenue and tripled the number of ethical hackers registered on its platform. The company has also developed integrated pentest and attack surface management solutions, offering customers a unified approach to monitoring their online risks and vulnerabilities.
Guillaume Vassault-Houlière, CEO and Co-Founder of YesWeHack, commented: “This funding round is a vote of confidence in our commitment to excellence and our ambitious vision. Thanks to this investment, YesWeHack will deliver even higher levels of customer satisfaction and continue developing innovative solutions in one of the most dynamic segments of cybersecurity. We would like to thank our investors, both longstanding and new, and are honoured by their trust.”
Antoine Izsak, Head of Growth Equity at Wendel, said: “Bug bounty is now recognised as a must by some of the companies most exposed to the cyber threat. We are delighted to be working with the European leader YesWeHack, which stands out for its quality of service, compliance with regulations and the relevance of its technological roadmap for customers who are increasingly overwhelmed by the growing volume of vulnerabilities."
Renaud Deraison, Co-Founder of Tenable, Senior Advisor to Wendel Growth and new member of the Board of Directors added:"YesWeHack's community of experts is one of the most qualified in the world to continuously test the security of its customers' digital infrastructure. I'm honoured to join YesWeHack's Board of Directors and look forward to contributing to the company's mission alongside Guillaume and his team."
*The Corporate Venture Capital fund of CNP Assurances.
**The CAC 40 is Paris’ main stock market index.
About YesWeHack
YesWeHack is a leading Bug Bounty and Vulnerability Management Platform. Founded by ethical hackers in 2015, YesWeHack connects organisations worldwide to tens of thousands of ethical hackers, who uncover vulnerabilities in websites, mobile apps, connected devices and digital infrastructure.
Our Bug Bounty Programs benefit from in-house triage, personalised support, a customisable model and results-based pricing. Clients include Tencent, Swiss Post, Telenor, Ooredoo, Orange, the French Ministry of Armed Forces and several other governments worldwide.
The YesWeHack platform offers a range of integrated, API-based solutions: Bug Bounty (crowdsourcing vulnerability discovery), Vulnerability Disclosure Policy (creating and managing a secure channel for external vulnerability reporting), Pentest Management (managing pentest reports from all sources) and Attack Surface Management (continuously mapping online exposure and detecting attack vectors).
For more information, visit: www.yeswehack.com
This transaction was carried out with the expert support of Trachet Ltd.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610793319/en/
Contact information
Press
press@yeswehack.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 16:08:00 EEST | Press release
Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broadened the title’s availability by adding support for Nintendo Switch™ 2 at an early stage. As a res
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broadened the title’s availability by adding support for Nintendo Switch™ 2 at an early stage. As a res
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
